Table 3.
Overview of supposed sequelae of WMH in large-scale studies.
| Sequelae | Studies |
|---|---|
| Alzheimer's disease | (96–99) |
| Antidepressant Use | (100, 101) |
| Apathy symptoms | (102) |
| Brain atrophy | (181, 182, 184, 56, 172, 145) |
| Brain volumetric changes | (32, 162, 189) |
| Callosum atrophy | (103, 104) |
| Cerebral blood flow | (105) |
| Cognitive function | (21, 56, 62, 95, 153, 79, 104, 134, 140, 143, 155, 156, 160, 164, 166, 169, 170, 180, 188–190, 194, 195) |
| Death | (106) |
| Depressive symptoms | (100, 101, 154,133,147, 151, 177, 139) |
| Falls | (107) |
| Functional status | (108) |
| Grief | (109) |
| Headache | (110–112) |
| Immobility | (57) |
| Manual dexterity | (113) |
| Migraine | (110, 112) |
| Mild cognitive impairment | (98, 137, 185, 157) |
| Olfactory function | (114) |
| Perivascular spaces | (115) |
| Restless-Legs-syndrome | (116) |
| Retinal Microvasculature | (117) |
| Study-drop-out | (118) |
| Subjective memory Impairment | (119) |
| Tract Integrity | (120) |
Significant associations with WMH indicated in bold.